How Does Sivextro Work Against Skin Infections?
Sivextro (tedizolid) is an oxazolidinone antibiotic approved for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including MRSA. It inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, with once-daily IV or oral dosing for 6 days.[1]
Sivextro vs. Linezolid in Clinical Trials
In phase 3 ESTABLISH trials (1 and 2), Sivextro met non-inferiority to linezolid (also an oxazolidinone) for early clinical response in ABSSSI patients. ESTABLISH-1 showed 92.9% success for tedizolid vs. 91.5% for linezolid (difference 1.4%, 95% CI -2.0 to 4.9%). ESTABLISH-2 found 88.2% vs. 86.5% (difference 1.7%, 95% CI -2.0 to 5.4%). Tedizolid had fewer adverse events, especially gastrointestinal.[2][3]
No trials show Sivextro superior in efficacy; it's non-inferior, with potential tolerability edge.
Comparison to Vancomycin and Daptomycin
Guidelines (IDSA 2014) list Sivextro as an alternative for ABSSSI, not first-line. Vancomycin remains standard for MRSA skin infections due to cost and familiarity. No head-to-head trials exist against vancomycin or daptomycin, but pooled data suggest similar cure rates (85-95%) across agents for uncomplicated cases. Tedizolid may penetrate skin better and require shorter duration, but evidence doesn't prove higher effectiveness.[4][5]
| Agent | Typical Success Rate in ABSSSI Trials | Dosing | Key Notes |
|-------|-------------------------------------|--------|-----------|
| Sivextro | 88-93% | 200 mg daily x6 days | Oral switch possible; less myelosuppression |
| Linezolid | 86-92% | 600 mg BID x10-14 days | More GI side effects |
| Vancomycin | 85-90% | IV weight-based | Nephrotoxicity risk; monitoring needed |
| Daptomycin | 90-96% | 4 mg/kg daily | Muscle toxicity; not oral |
When Might Sivextro Be Preferred?
Use Sivextro for patients intolerant to linezolid (e.g., thrombocytopenia risk lower at short courses) or needing oral therapy. It's not more effective overall but suits outpatient transitions. Resistance patterns matter—both oxazolidinones retain activity against most MRSA, unlike rising vancomycin MICs.[6]
Limitations and Real-World Data
Post-approval studies show comparable outcomes to standard care, but no randomized superiority data. Cost is higher (~$2,500/course vs. $300 for vancomycin).[7] FDA labels emphasize non-inferiority, not better efficacy.[1]
[1]: Sivextro Prescribing Information
[2]: Prokocimer et al., Clin Infect Dis 2013
[3]: Prokocimer et al., Clin Infect Dis 2014
[4]: IDSA ABSSSI Guidelines 2014
[5]: Lipsky et al., Clin Infect Dis 2016
[6]: CDC MRSA Report 2023
[7]: DrugPatentWatch.com - Sivextro Pricing